1. Medtech Insight
  2. >>Device Area
  3. >>Surgery

J&J Medtech’s FDA-Cleared DUALTO System Prepares For Future Use With OTTAVA Robotic Platform

Future-Ready Surgical Energy Platform Designed For Flexibility, Precision And Robotic Integration

 
• By Shubham Singh

DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.

Designed to consolidate multiple energy modalities into a single platform, DUALTO also incorporates connectivity features and modular configurations that support broader digital integration.
Key Takeaways
  • DUALTO is FDA-cleared to consolidate four energy modalities into one system, with a modular, dual-surgeon configuration and a single touchscreen interface for streamlined workflows. 
  • The system is cloud-connected via Polyphonic Fleet, enabling real-time monitoring, remote software updates, and data-driven equipment management for hospitals. 
  • Designed with future compatibility in mind, DUALTO will integrate with J&J’s upcoming OTTAVA robotic system, positioning it as a future-ready surgical platform. 

J&J MedTech’s DUALTO Energy System, recently cleared by the FDA, is not only built to replace multiple legacy generators–it’s also designed with robotic compatibility in mind, including future integration with...

Designed to consolidate multiple energy modalities into a single platform, DUALTO also incorporates connectivity features and modular configurations that support broader digital integration. According to the company, these capabilities will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Robotic Surgery

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.